These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 20083143)

  • 1. Novel endomorphin analogues with antagonist activity at the mu-opioid receptor in the gastrointestinal tract.
    Fichna J; Gach K; Perlikowska R; Cravezic A; Bonnet JJ; do-Rego JC; Janecka A; Storr MA
    Regul Pept; 2010 Jun; 162(1-3):109-14. PubMed ID: 20083143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mu-opioid receptor-selective peptide antagonists, antanal-1 and antanal-2, produce anticonvulsant effects in mice.
    Fichna J; Socała K; Nieoczym D; Gach K; Perlikowska R; Janecka A; Wlaź P
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():126-31. PubMed ID: 22918032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and characterization of potent and selective mu-opioid receptor antagonists, [Dmt(1), D-2-Nal(4)]endomorphin-1 (Antanal-1) and [Dmt(1), D-2-Nal(4)]endomorphin-2 (Antanal-2).
    Fichna J; do-Rego JC; Chung NN; Lemieux C; Schiller PW; Poels J; Broeck JV; Costentin J; Janecka A
    J Med Chem; 2007 Feb; 50(3):512-20. PubMed ID: 17266203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical studies of opioids and opioid antagonists on gastrointestinal function.
    Greenwood-Van Meerveld B; Gardner CJ; Little PJ; Hicks GA; Dehaven-Hudkins DL
    Neurogastroenterol Motil; 2004 Oct; 16 Suppl 2():46-53. PubMed ID: 15357851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro characterization of the effects of endomorphin 1 and 2, endogenous ligands for mu-opioid receptors, on mouse colonic motility.
    Yu Y; Cui Y; Wang X; Lai LH; Wang CL; Fan YZ; Liu J; Wang R
    Biochem Pharmacol; 2007 May; 73(9):1384-93. PubMed ID: 17274956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide opioid antagonist separates peripheral and central opioid antitransit effects.
    Shook JE; Pelton JT; Hruby VJ; Burks TF
    J Pharmacol Exp Ther; 1987 Nov; 243(2):492-500. PubMed ID: 2824748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood-brain barrier permeability and bioavailability of a highly potent and mu-selective opioid receptor antagonist, CTAP: comparison with morphine.
    Abbruscato TJ; Thomas SA; Hruby VJ; Davis TP
    J Pharmacol Exp Ther; 1997 Jan; 280(1):402-9. PubMed ID: 8996221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
    Baker AK; Meert TF
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel highly potent mu-opioid receptor antagonist based on endomorphin-2 structure.
    Fichna J; do-Rego JC; Janecki T; Staniszewska R; Poels J; Broeck JV; Costentin J; Schiller PW; Janecka A
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1350-3. PubMed ID: 18207400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of mu-opioid receptors in antinociception and inhibition of gastrointestinal transit induced by 7-hydroxymitragynine, isolated from Thai herbal medicine Mitragyna speciosa.
    Matsumoto K; Hatori Y; Murayama T; Tashima K; Wongseripipatana S; Misawa K; Kitajima M; Takayama H; Horie S
    Eur J Pharmacol; 2006 Nov; 549(1-3):63-70. PubMed ID: 16978601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mu opioid antagonist properties of a cyclic somatostatin octapeptide in vivo: identification of mu receptor-related functions.
    Shook JE; Pelton JT; Lemcke PK; Porreca F; Hruby VJ; Burks TF
    J Pharmacol Exp Ther; 1987 Jul; 242(1):1-7. PubMed ID: 2886635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential influence of D1 and D2 dopamine receptors on acute opiate withdrawal in guinea-pig isolated ileum.
    Capasso A; Sorrentino L
    Br J Pharmacol; 1997 Mar; 120(6):1001-6. PubMed ID: 9134209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale, design, and synthesis of novel phenyl imidazoles as opioid receptor agonists for gastrointestinal disorders.
    Breslin HJ; Miskowski TA; Rafferty BM; Coutinho SV; Palmer JM; Wallace NH; Schneider CR; Kimball ES; Zhang SP; Li J; Colburn RW; Stone DJ; Martinez RP; He W
    J Med Chem; 2004 Oct; 47(21):5009-20. PubMed ID: 15456245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence.
    Wang D; Raehal KM; Lin ET; Lowery JJ; Kieffer BL; Bilsky EJ; Sadée W
    J Pharmacol Exp Ther; 2004 Feb; 308(2):512-20. PubMed ID: 14600246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mu-opioid receptor ligands lack receptor subtype selectivity in the aequorin luminescence-based calcium assay.
    Fichna J; Staniszewska R; Poels J; Vanden Broeck J; Janecka A
    Chem Biol Drug Des; 2007 Sep; 70(3):247-53. PubMed ID: 17718719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic arthritis down-regulates peripheral mu-opioid receptor expression with concomitant loss of endomorphin 1 antinociception.
    Li Z; Proud D; Zhang C; Wiehler S; McDougall JJ
    Arthritis Rheum; 2005 Oct; 52(10):3210-9. PubMed ID: 16200625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphine withdrawal syndrome and its prevention with baclofen: Autoradiographic study of mu-opioid receptors in prepubertal male and female mice.
    Diaz SL; Barros VG; Antonelli MC; Rubio MC; Balerio GN
    Synapse; 2006 Aug; 60(2):132-40. PubMed ID: 16715492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of novel peripherally active morphiceptin analogs.
    Gach K; do-Rego JC; Fichna J; Storr M; Delbro D; Toth G; Janecka A
    Peptides; 2010 Aug; 31(8):1617-24. PubMed ID: 20434497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endomorphin-1 analogues (MELs) penetrate the blood-brain barrier and exhibit good analgesic effects with minimal side effects.
    Wang Y; Liu X; Wang D; Yang J; Zhao L; Yu J; Wang R
    Neuropharmacology; 2015 Oct; 97():312-21. PubMed ID: 26116761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.